Valence8 US LP Invests $561,000 in Eli Lilly and Company (NYSE:LLY)

Valence8 US LP bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 633 shares of the company’s stock, valued at approximately $561,000. Eli Lilly and Company makes up about 0.2% of Valence8 US LP’s holdings, making the stock its 19th largest position.

Several other institutional investors have also bought and sold shares of the stock. Westwood Holdings Group Inc. raised its holdings in shares of Eli Lilly and Company by 5.4% in the first quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock valued at $2,987,000 after purchasing an additional 196 shares during the last quarter. Guardian Capital LP grew its position in Eli Lilly and Company by 3.0% in the 1st quarter. Guardian Capital LP now owns 921 shares of the company’s stock worth $717,000 after purchasing an additional 27 shares in the last quarter. Linscomb Wealth Inc. increased its stake in Eli Lilly and Company by 0.5% in the 1st quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock valued at $2,637,000 after buying an additional 17 shares during the last quarter. Steel Grove Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 104.9% during the 1st quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock worth $618,000 after buying an additional 407 shares in the last quarter. Finally, Beck Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 1.9% in the 1st quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock worth $6,865,000 after buying an additional 163 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LLY. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Finally, Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Price Performance

LLY stock opened at $748.91 on Friday. The firm has a 50 day moving average of $868.53 and a 200-day moving average of $869.14. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The firm has a market capitalization of $710.96 billion, a P/E ratio of 80.96, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter last year, the business posted $0.10 EPS. The company’s quarterly revenue was up 20.4% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.